120 related articles for article (PubMed ID: 9533548)
1. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.
Zamboni WC; Gajjar AJ; Heideman RL; Beijnen JH; Rosing H; Houghton PJ; Stewart CF
Clin Cancer Res; 1998 Mar; 4(3):783-9. PubMed ID: 9533548
[TBL] [Abstract][Full Text] [Related]
2. Using plasma topotecan pharmacokinetics to estimate topotecan exposure in cerebrospinal fluid of children with medulloblastoma.
Freeman BB; Iacono LC; Panetta JC; Gajjar A; Stewart CF
Neuro Oncol; 2006 Apr; 8(2):89-95. PubMed ID: 16461424
[TBL] [Abstract][Full Text] [Related]
3. Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor.
Stewart CF; Iacono LC; Chintagumpala M; Kellie SJ; Ashley D; Zamboni WC; Kirstein MN; Fouladi M; Seele LG; Wallace D; Houghton PJ; Gajjar A
J Clin Oncol; 2004 Aug; 22(16):3357-65. PubMed ID: 15310781
[TBL] [Abstract][Full Text] [Related]
4. No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients.
Zackrisson AL; Malmström H; Peterson C
Eur J Clin Pharmacol; 2002 May; 58(2):103-8. PubMed ID: 12012141
[TBL] [Abstract][Full Text] [Related]
5. A four-hour topotecan infusion achieves cytotoxic exposure throughout the neuraxis in the nonhuman primate model: implications for treatment of children with metastatic medulloblastoma.
Zamboni WC; Gajjar AJ; Mandrell TD; Einhaus SL; Danks MK; Rogers WP; Heideman RL; Houghton PJ; Stewart CF
Clin Cancer Res; 1998 Oct; 4(10):2537-44. PubMed ID: 9796988
[TBL] [Abstract][Full Text] [Related]
6. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.
Rose PG; Gordon NH; Fusco N; Fluellen L; Rodriguez M; Ingalls ST; Hoppel CL
Gynecol Oncol; 2000 Aug; 78(2):228-34. PubMed ID: 10926808
[TBL] [Abstract][Full Text] [Related]
7. Pilot study assessing a seven-day continuous intrathecal topotecan infusion for recurrent or progressive leptomeningeal metastatic cancer.
Tran HC; Gardner S; Weiner HL; Liebes LF; Finlay JL
J Oncol Pharm Pract; 2014 Jun; 20(3):229-32. PubMed ID: 23929729
[TBL] [Abstract][Full Text] [Related]
8. Determination of plasma topotecan and its metabolite N-desmethyl topotecan as both lactone and total form by reversed-phase liquid chromatography with fluorescence detection.
Bai F; Kirstein MN; Hanna SK; Iacono LC; Johnston B; Stewart CF
J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Feb; 784(2):225-32. PubMed ID: 12505770
[TBL] [Abstract][Full Text] [Related]
9. Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer.
Herben VM; ten Bokkel Huinink WW; Schot ME; Hudson I; Beijnen JH
Anticancer Drugs; 1998 Jun; 9(5):411-8. PubMed ID: 9660538
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors.
Baker SD; Heideman RL; Crom WR; Kuttesch JF; Gajjar A; Stewart CF
Cancer Chemother Pharmacol; 1996; 37(3):195-202. PubMed ID: 8529278
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan.
Akhtar S; Beckman RA; Mould DR; Doyle E; Fields SZ; Wright J
Cancer Chemother Pharmacol; 2000; 46(3):204-10. PubMed ID: 11021737
[TBL] [Abstract][Full Text] [Related]
12. Topotecan lacks third space sequestration.
Gelderblom H; Loos WJ; Verweij J; de Jonge MJ; Sparreboom A
Clin Cancer Res; 2000 Apr; 6(4):1288-92. PubMed ID: 10778953
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor.
Abbruzzese JL; Madden T; Sugarman SM; Ellis AL; Loughlin S; Hess KR; Newman RA; Zwelling LA; Raber MN
Clin Cancer Res; 1996 Sep; 2(9):1489-97. PubMed ID: 9816325
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity.
Stewart CF; Baker SD; Heideman RL; Jones D; Crom WR; Pratt CB
J Clin Oncol; 1994 Sep; 12(9):1946-54. PubMed ID: 8083716
[TBL] [Abstract][Full Text] [Related]
15. Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors.
Zamboni WC; Bowman LC; Tan M; Santana VM; Houghton PJ; Meyer WH; Pratt CB; Heideman RL; Gajjar AJ; Pappo AS; Stewart CF
Cancer Chemother Pharmacol; 1999; 43(6):454-60. PubMed ID: 10321504
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics of topotecan.
Herben VM; ten Bokkel Huinink WW; Beijnen JH
Clin Pharmacokinet; 1996 Aug; 31(2):85-102. PubMed ID: 8853931
[TBL] [Abstract][Full Text] [Related]
17. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.
Thompson J; George EO; Poquette CA; Cheshire PJ; Richmond LB; de Graaf SS; Ma M; Stewart CF; Houghton PJ
Clin Cancer Res; 1999 Nov; 5(11):3617-31. PubMed ID: 10589779
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetic analysis of topotecan in pediatric cancer patients.
Schaiquevich P; Panetta JC; Iacono LC; Freeman BB; Santana VM; Gajjar A; Stewart CF
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6703-11. PubMed ID: 18006771
[TBL] [Abstract][Full Text] [Related]
19. Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion.
Zamboni WC; Houghton PJ; Johnson RK; Hulstein JL; Crom WR; Cheshire PJ; Hanna SK; Richmond LB; Luo X; Stewart CF
J Pharmacol Exp Ther; 1998 Jan; 284(1):89-94. PubMed ID: 9435165
[TBL] [Abstract][Full Text] [Related]
20. A phase I and pharmacokinetic study of intraperitoneal topotecan.
Hofstra LS; Bos AM; de Vries EG; van der Zee AG; Beijnen JH; Rosing H; Mulder NH; Aalders JG; Willemse PH
Br J Cancer; 2001 Nov; 85(11):1627-33. PubMed ID: 11742479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]